MX2020003606A - Tratamiento del sindrome del cromosoma x fragil con canabidiol. - Google Patents
Tratamiento del sindrome del cromosoma x fragil con canabidiol.Info
- Publication number
- MX2020003606A MX2020003606A MX2020003606A MX2020003606A MX2020003606A MX 2020003606 A MX2020003606 A MX 2020003606A MX 2020003606 A MX2020003606 A MX 2020003606A MX 2020003606 A MX2020003606 A MX 2020003606A MX 2020003606 A MX2020003606 A MX 2020003606A
- Authority
- MX
- Mexico
- Prior art keywords
- fragile
- syndrome
- cannabidiol
- treatment
- subject
- Prior art date
Links
- 208000001914 Fragile X syndrome Diseases 0.000 title abstract 3
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 title abstract 3
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 title abstract 3
- 229950011318 cannabidiol Drugs 0.000 title abstract 3
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 title abstract 3
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 title abstract 3
- 208000013404 behavioral symptom Diseases 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente tecnología se refiere a un método de tratamiento de uno o más síntomas de conducta del síndrome del cromosoma X frágil en un sujeto, mediante la administración transdérmica de una cantidad eficaz de canabidiol (CBD) al sujeto, con lo que son tratados en el sujeto uno o más síntomas de conducta del síndrome del cromosoma X frágil.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762564834P | 2017-09-28 | 2017-09-28 | |
| US201862632532P | 2018-02-20 | 2018-02-20 | |
| PCT/IB2018/057519 WO2019064234A1 (en) | 2017-09-28 | 2018-09-27 | TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020003606A true MX2020003606A (es) | 2020-10-28 |
Family
ID=63878731
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020003606A MX2020003606A (es) | 2017-09-28 | 2018-09-27 | Tratamiento del sindrome del cromosoma x fragil con canabidiol. |
| MX2022012424A MX2022012424A (es) | 2017-09-28 | 2020-07-13 | Tratamiento del sindrome del cromosoma x fragil con canabidiol. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012424A MX2022012424A (es) | 2017-09-28 | 2020-07-13 | Tratamiento del sindrome del cromosoma x fragil con canabidiol. |
Country Status (21)
| Country | Link |
|---|---|
| US (11) | US10213390B1 (es) |
| EP (2) | EP3967301B1 (es) |
| JP (3) | JP7210564B2 (es) |
| KR (2) | KR20220045070A (es) |
| AU (1) | AU2018343256A1 (es) |
| BR (1) | BR112020005918A2 (es) |
| CA (1) | CA3077330A1 (es) |
| CY (1) | CY1125071T1 (es) |
| DK (1) | DK3687513T3 (es) |
| ES (1) | ES2907325T3 (es) |
| HR (1) | HRP20220277T1 (es) |
| HU (1) | HUE058102T2 (es) |
| IL (1) | IL273495A (es) |
| JO (1) | JOP20200082A1 (es) |
| LT (1) | LT3687513T (es) |
| MX (2) | MX2020003606A (es) |
| PL (1) | PL3687513T3 (es) |
| PT (1) | PT3687513T (es) |
| RS (1) | RS62969B1 (es) |
| SI (1) | SI3687513T1 (es) |
| WO (1) | WO2019064234A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20220277T1 (hr) | 2017-09-28 | 2022-05-13 | Zynerba Pharmaceuticals, Inc. | Liječenje fragilnog x sindroma i autizma kanabidiolom |
| GB201912760D0 (en) * | 2019-09-05 | 2019-10-23 | Healx Ltd | Treatment |
| US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| GB2589306A (en) * | 2019-10-25 | 2021-06-02 | Gw Res Ltd | Use of cannabidiol preparations in the treatment of fragile X syndrome |
| KR102398219B1 (ko) | 2020-02-07 | 2022-05-17 | 주식회사 뉴로벤티 | 릴메니딘 화합물을 유효성분으로 포함하는 취약 x 증후군 또는 관련 발달 장애 치료용 조성물 |
| AU2021281118A1 (en) * | 2020-05-26 | 2023-01-05 | Zynerba Pharmaceuticals, Inc. | Treatment of autism spectrum disorder with cannabidiol |
| EP4171528A1 (en) * | 2020-06-29 | 2023-05-03 | Zynerba Pharmaceuticals, Inc. | Treatment of fragile x syndrome with cannabidiol |
| IL303388A (en) * | 2020-12-03 | 2023-08-01 | Zynerba Pharmaceuticals Inc | Treatment of refractory convulsions |
| CN118284412A (zh) * | 2021-10-22 | 2024-07-02 | Zyne制药公司 | 伴中度至重度焦虑和/或社交回避的自闭症谱系障碍受试者易怒症的治疗 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8449908B2 (en) | 2000-12-22 | 2013-05-28 | Alltranz, Llc | Transdermal delivery of cannabidiol |
| FI20020333A0 (fi) | 2002-02-20 | 2002-02-20 | Tomi Jaervinen | Metyloidun syklodekstriinin uudet kompleksit |
| US20080139472A1 (en) * | 2006-10-06 | 2008-06-12 | The Regents Of The University Of California | Upregulating bdnf levels to mitigate mental retardation |
| ES2534900T3 (es) | 2007-07-30 | 2015-04-30 | Zynerba Pharmaceuticals, Inc. | Profármacos de cannabidiol, composiciones que comprenden los profármacos de cannabidiol y métodos de uso de los mismos |
| EP2424525A1 (en) | 2009-04-28 | 2012-03-07 | AllTranz Inc. | Formulations of cannabidiol and methods of using the same |
| US20110052694A1 (en) | 2009-08-31 | 2011-03-03 | Alltranz Inc. | Use of cannabidiol prodrugs in topical and transdermal administration with microneedles |
| CN105209424B (zh) | 2013-01-08 | 2019-12-13 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 氟化的cbd化合物、组合物和其用途 |
| AU2014340709B2 (en) | 2013-10-29 | 2019-07-04 | Echo Pharmaceuticals B.V. | Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders |
| US20160022627A2 (en) | 2014-04-18 | 2016-01-28 | Mary's Medicinals LLC | Transdermal cannabinoid patch |
| US20170224634A1 (en) | 2014-05-29 | 2017-08-10 | Insys Development Company, Inc. | Stable cannabinoid formulations |
| US11331279B2 (en) | 2014-05-29 | 2022-05-17 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
| CN114191420A (zh) | 2014-05-29 | 2022-03-18 | 雷迪厄斯制药公司 | 稳定的大麻素类化合物制剂 |
| US20160271252A1 (en) | 2014-05-29 | 2016-09-22 | Insys Development Company, Inc. | Stable cannabinoid formulations |
| CA2953684C (en) | 2014-06-27 | 2023-01-03 | Kenton L. Crowley | Buccal and sublingual cannabinoid formulations and method of making the same |
| US20160000843A1 (en) | 2014-07-01 | 2016-01-07 | MJAR Holdings, LLC | High cannabidiol cannabis strains |
| CA2965493C (en) | 2014-10-21 | 2021-12-07 | United Cannabis Corp. | Cannabis extracts and methods of preparing and using same |
| US9375417B2 (en) | 2014-12-04 | 2016-06-28 | Mary's Medicinals LLC | Transdermal cannabinoid formulations |
| US20190125779A1 (en) | 2014-12-30 | 2019-05-02 | University Of Houston System | Pharmaceutical compositions |
| US20160338974A1 (en) | 2015-03-02 | 2016-11-24 | Afgin Pharma, Llc | Topical regional neuro affective therapy with cannabinoid combination products |
| CA2978605A1 (en) | 2015-03-02 | 2016-09-09 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with cannabinoids |
| WO2017068349A1 (en) | 2015-10-23 | 2017-04-27 | E-Therapeutics Plc | Cannabinoid for use in immunotherapy |
| WO2017151980A1 (en) | 2016-03-03 | 2017-09-08 | Segreti Louis M | Cannabis-based bioactive formulations and methods for use thereof |
| EP3423033A4 (en) | 2016-03-04 | 2020-01-01 | Sharon Anavi-Goffer | SELF-EMULSIFYING COMPOSITIONS OF CB2 RECEPTOR MODULATORS |
| CA3017696A1 (en) | 2016-03-16 | 2017-09-21 | Buzzelet Development And Technologies Ltd | Terpene-enriched cannabinoid composition |
| GB2549278B (en) | 2016-04-11 | 2021-02-17 | Gw Res Ltd | Use of cannabidivarin in the treatment of autism spectrum disorder |
| GB2549277B (en) | 2016-04-11 | 2021-02-17 | Gw Res Ltd | Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder |
| EP3445179A4 (en) | 2016-04-19 | 2020-07-22 | Canna-B Cure Ltd | ENZYMATICALLY TREATED THERAPEUTIC COMPOSITION ENRICHED IN CANNABIS |
| BR112018075073A2 (pt) | 2016-06-02 | 2019-04-30 | Acerus Pharmaceutical Corporation | composições nasais de canabidiol |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
| HRP20220277T1 (hr) | 2017-09-28 | 2022-05-13 | Zynerba Pharmaceuticals, Inc. | Liječenje fragilnog x sindroma i autizma kanabidiolom |
| MX2021007076A (es) | 2018-12-14 | 2021-08-11 | Zynerba Pharmaceuticals Inc | Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol. |
| AU2021281118A1 (en) | 2020-05-26 | 2023-01-05 | Zynerba Pharmaceuticals, Inc. | Treatment of autism spectrum disorder with cannabidiol |
| EP4171528A1 (en) | 2020-06-29 | 2023-05-03 | Zynerba Pharmaceuticals, Inc. | Treatment of fragile x syndrome with cannabidiol |
-
2018
- 2018-09-27 HR HRP20220277TT patent/HRP20220277T1/hr unknown
- 2018-09-27 DK DK18788905.0T patent/DK3687513T3/da active
- 2018-09-27 MX MX2020003606A patent/MX2020003606A/es unknown
- 2018-09-27 US US16/144,632 patent/US10213390B1/en active Active
- 2018-09-27 KR KR1020227010520A patent/KR20220045070A/ko not_active Application Discontinuation
- 2018-09-27 PT PT187889050T patent/PT3687513T/pt unknown
- 2018-09-27 WO PCT/IB2018/057519 patent/WO2019064234A1/en active Application Filing
- 2018-09-27 SI SI201830564T patent/SI3687513T1/sl unknown
- 2018-09-27 BR BR112020005918-8A patent/BR112020005918A2/pt unknown
- 2018-09-27 LT LTEPPCT/IB2018/057519T patent/LT3687513T/lt unknown
- 2018-09-27 EP EP21206188.1A patent/EP3967301B1/en active Active
- 2018-09-27 HU HUE18788905A patent/HUE058102T2/hu unknown
- 2018-09-27 EP EP18788905.0A patent/EP3687513B1/en active Active
- 2018-09-27 CA CA3077330A patent/CA3077330A1/en active Pending
- 2018-09-27 RS RS20220123A patent/RS62969B1/sr unknown
- 2018-09-27 ES ES18788905T patent/ES2907325T3/es active Active
- 2018-09-27 KR KR1020207012201A patent/KR20200058513A/ko not_active Application Discontinuation
- 2018-09-27 AU AU2018343256A patent/AU2018343256A1/en active Pending
- 2018-09-27 JP JP2020517930A patent/JP7210564B2/ja active Active
- 2018-09-27 PL PL18788905T patent/PL3687513T3/pl unknown
- 2018-09-27 JO JOP/2020/0082A patent/JOP20200082A1/ar unknown
- 2018-12-14 US US16/220,249 patent/US10314792B2/en active Active
-
2019
- 2019-01-16 US US16/249,732 patent/US10471022B2/en active Active
- 2019-05-14 US US16/411,248 patent/US10568848B2/en active Active
- 2019-10-07 US US16/594,317 patent/US10758497B2/en active Active
-
2020
- 2020-01-08 US US16/737,326 patent/US20200214995A1/en not_active Abandoned
- 2020-03-22 IL IL273495A patent/IL273495A/en unknown
- 2020-07-13 MX MX2022012424A patent/MX2022012424A/es unknown
- 2020-08-06 US US16/986,622 patent/US11458110B2/en active Active
-
2021
- 2021-09-02 US US17/465,141 patent/US20220096396A1/en not_active Abandoned
-
2022
- 2022-02-03 JP JP2022015432A patent/JP2022064988A/ja active Pending
- 2022-02-22 CY CY20221100148T patent/CY1125071T1/el unknown
- 2022-08-24 US US17/895,008 patent/US11779549B2/en active Active
-
2023
- 2023-01-10 JP JP2023001500A patent/JP2023040166A/ja active Pending
- 2023-03-21 US US18/124,460 patent/US20230364028A1/en active Pending
- 2023-08-30 US US18/458,727 patent/US20230414533A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020003606A (es) | Tratamiento del sindrome del cromosoma x fragil con canabidiol. | |
| CL2018003213A1 (es) | Inhibidores enzimáticos. | |
| AR093386A1 (es) | Composicion para tratar la diabetes o la diabesidad que comprende un analogo de oxintomodulina y metodo de tratamiento | |
| BR112018002046A2 (pt) | métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina | |
| EA201591761A1 (ru) | Композиции на основе наночастиц | |
| BR112018004680A2 (pt) | método de tratamento de distúrbios de desenvolvimento | |
| EA201692204A1 (ru) | Композиции и способы модулирования экспрессии фактора комплемента b | |
| BR112017006113A2 (pt) | combinações sinérgicas de auristatina | |
| MX2020010269A (es) | Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa. | |
| BR112019005040A2 (pt) | aplicação de pridopidina para tratamento de síndrome de rett | |
| PH12017501806A1 (en) | Anthelmintic combinations and methods of use thereof | |
| NI201700057A (es) | Método para tratar, prevenir o reducir el riesgo de infección cutánea | |
| MX2021007076A (es) | Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol. | |
| AR112405A1 (es) | Tratamiento de cáncer de mama triple negativo o cáncer colorrectal con metástasis hepáticas | |
| EA201690075A1 (ru) | Способ лечения внутриклеточной инфекции | |
| BR112016012248A2 (pt) | método de tratamento de nefropatia | |
| AR100734A1 (es) | Método para tratar leucemia linfocítica crónica (cll) | |
| AR095483A1 (es) | Composición y método para prevenir, reducir, aliviar o tratar el vómito idiopático | |
| MX2020001769A (es) | Composiciones y metodos para inhibir patogenos de plantas. | |
| MX2019012659A (es) | Metodos para tratar ateroesclerosis con neutralizadores gamma-cetoaldehido. | |
| MX369039B (es) | Vacuna contra el circovirus porcino tipo 2. | |
| CL2012003202A1 (es) | Metodo para tratar una infeccion gastrointestinal recurrente de clostridium difficile, que comprende la administracion de fidaxomicina y donde el sujeto ha sido sometido a un tratamiento previo para combatir dicha infeccion. | |
| BR112017005532A2 (pt) | acionamento por correia com extensão de compressão | |
| BR112015023260A2 (pt) | método de tratamento de grão com ozônio | |
| EA201690950A1 (ru) | Средства и способ предотвращения миграции танина из древесины |